In this article, we will discuss the Top 10 Small Cap Stocks With Huge Growth Potential.
One of the key takeaways from Franklin Templeton’s Talking Markets podcast, published on May 14, was that for years, small-cap stocks were the market’s afterthought, overshadowed by the mega-cap names that dominated headlines and index returns. That story is changing, according to the podcast’s participants; Chris Galipeau of the Franklin Templeton Institute and Frank Gannon of Royce Investment Partners.
They noted that since the year started in April 2026, the Russell 2000 was up approximately 13.3%. In comparison, the S&P 500 only gained 6% in that period. The Russell 2000 Value index also led major US indices at over 15%, they added. Despite this run, Gannon noted that small caps remain the “forgotten asset class,” with most investors still significantly underweight.
For Galipeau, the macro environment underpinning this rally is, by most accounts, durable. He pointed to sustained big-tech capital expenditure spending, a robust US consumer, and the fiscal boost from the One Big Beautiful Bill. The latter has driven tax refunds roughly 15% higher than last year, which has put an estimated $100-150 billion back into consumers’ pockets.
Both guests noted that small-cap earnings were negative through 2023 and 2024, and that they turned positive by the end of 2025. They believe that that turn around will carry into this year and even 2027, which is why they expect small-cap EPS growth to outpace large-cap growth in these two years. The reason this turnaround will hold is, as per Gannon, down to five factors, including reshoring, deregulation, artificial intelligence adoption, Federal Reserve rate easing, and capital-friendly treatment of CapEx and R&D under the new tax law.
The AI trade, typically associated with mega-cap names, is also a major tailwind for smaller stocks, according to Steve Sosnick, chief strategist at Interactive Brokers. Sosnick told Barron’s: “We’re seeing waves of speculation in areas like quantum computing, space exploration, alongside waves of AI spending that are boosting not only the big names, but small ones too. That is also a catalyst for small cap investing overall. Hence, the rally in the key small cap index despite some obvious macro headwinds.”
With that backdrop in mind, this article presents 10 small cap stocks best positioned to capitalize on this opportunity.
Our Methodology
To compile this list, we used Finviz and Yahoo stock screeners to identify US-listed companies with a market capitalization between $300 million and $2 billion as of May 28, 2026, and picked names that analysts were bullish on. We ensured that the stocks had an upside potential of at least 50%, indicating strong Wall Street optimism. Next, we selected the 10 most popular among elite hedge funds as of Q1 2026. We sourced the hedge fund data from Insider Monkey’s database. The stocks are ranked in ascending order of upside.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Top Small Cap Stocks With Huge Growth Potential
10. Arlo Technologies, Inc. (NYSE:ARLO)
Stock Upside: 65.55%
Market Capitalization: $1.45 billion
Number of Hedge Fund Holders: 33
Arlo Technologies, Inc. (NYSE:ARLO) is one of the top small cap stocks with huge growth potential. On May 18, investment bank Oppenheimer initiated coverage on Arlo Technologies, Inc. with an Outperform rating and a price target of $20.
Martin Yang based his bullish case for Arlo on the company’s transformation as a business. This is in reference to the fact that Arlo has moved away from being a low-cost camera seller and reinvented itself as a premium, service-first platform that earns recurring revenue from its customers. Yang noted that subscriptions and services are now the backbone of Arlo’s business, which makes up 60% of total revenue and carry an 85% gross margin. He noted that the company’s annual recurring revenue in 2025 grew 28% to $330 million, which, in his analysis, underlines the strength and momentum of this shift.
Yang also pointed to Arlo’s partnerships with ADT, Samsung, and Comcast that he said have not yet been fully tapped for subscriber growth. In the analyst’s view, these relationships represent a multi-year opportunity to bring in new paying users, which gives Arlo a long runway ahead, even beyond what is already reflected in the numbers.
He also pointed to what he sees as a structural mispricing in the stock. Put simply, the analyst argues that the market has not yet properly valued Arlo as a services-led business, despite the clear shift in its revenue mix.
Arlo Technologies, Inc. is a smart home security company. It develops cloud-based platforms, wireless security cameras, video doorbells, floodlights, and alarm systems for residential and commercial users.
9. Critical Metals Corp. (NASDAQ:CRML)
Stock Upside: 67.43%
Market Capitalization: $1.75 billion
Number of Hedge Fund Holders: 20
Critical Metals Corp. (NASDAQ:CRML) is one of the top small cap stocks with huge growth potential. On May 21, Critical Metals Corp. announced the execution of a binding 15-year offtake agreement with US-based magnet maker REalloys Inc. The agreement covers rare-earth concentrate from Critical Metals’ flagship Tanbreez project in southern Greenland and formalizes and significantly expands a non-binding letter of intent the two companies signed in October 2025.
According to Critical Metals, the original letter of intent was a 10-year framework, but the new binding contract extends that to 15 years. It also adds two additional five-year renewal options, which in the company’s assessment, makes it one of the most substantial long-term heavy rare earth supply commitments in the Western world.
The company noted that the agreement allows REalloys to take 15% of Tanbreez’s annual Phase 1 rare earth concentrate output. REalloys also will have priority access to batches carrying elevated concentrations of dysprosium and terbium and a right of first refusal on additional volumes. Dysprosium and terbium are the two heavy rare-earth elements most critical to high-performance permanent magnets.
Deliveries will be priced against international rare earth oxide benchmarks on an element-by-element basis, said Critical Metals. It added that the concentrate will be shipped FOB from Tanbreez’s southern Greenland port, which benefits from year-round deep-water access directly to the North Atlantic.
Critical Metals Corp. is a mining and mineral exploration company. It focuses on acquiring and developing critical metals assets that support clean energy and advanced technologies.
8. AtriCure, Inc. (NASDAQ:ATRC)
Stock Upside: 67.76%
Market Capitalization: $1.45 billion
Number of Hedge Fund Holders: 27
AtriCure, Inc. (NASDAQ:ATRC) is one of the top small cap stocks with huge growth potential. On May 6, Needham reiterated its Buy rating and $45 price target on AtriCure, Inc. after the company delivered blowout Q1 2026 earnings.
AtriCure shared the earnings on May 5 and reported quarterly worldwide revenue of $141.2 million, a 14.3% jump year over year. This figure exceeded the analyst consensus estimate by about 1.4%. Mike Carrel, President and CEO, explained on the earnings call that this beat was made possible by a 28% growth in the pain management segment. This growth came on the back of the cryoSPHERE MAX probe. Other drivers the CEO pointed to are growth in the appendage management segment and open ablation.
Needham acknowledged the performance but noted that the key highlight that caught their attention was the accelerated timeline on the BoxX-NoAF clinical trial. This is a study testing a minimally invasive procedure to treat atrial fibrillation. AtriCure now expects patient enrollment to be complete by the end of this year, which is a whole 12 months ahead of its prior plan. This also means the trial results could be available in 2027 instead of 2028. For Needham, this is a major development because a positive data readout could unlock a major new market opportunity for AtriCure.
AtriCure, Inc. is a medical device company. It develops technologies for the treatment of atrial fibrillation and related cardiac conditions. Its products include ablation systems, surgical devices, and appendage management technologies used by cardiac surgeons and electrophysiologists worldwide.
7. Kemper Corporation (NYSE:KMPR)
Stock Upside: 71.94%
Market Capitalization: $1.51 billion
Number of Hedge Fund Holders: 35
Kemper Corporation (NYSE:KMPR) is one of the top small cap stocks with huge growth potential. On May 27, Kemper Corporation announced the appointment of Stephen J. McAnena as President and Chief Executive Officer, effective June 1. He will also join the Board of Directors, while Tom Evans, who served as Interim CEO, returns to his role as Executive Vice President, Secretary, and General Counsel.
McAnena brings more than 30 years of insurance industry experience across property and casualty, group benefits, life, and annuity sectors. He most recently served as Executive Vice President and Chief Operating Officer at Horace Mann, where he oversaw operations and strategic initiatives. His leadership background is expected to strengthen Kemper’s long‑term growth and execution.
Kemper also appointed Anthony J. DeSantis to its Board of Directors, effective June 1. With over 40 years of experience in personal and commercial lines, non‑standard auto, and distribution channels, DeSantis has held senior roles at American Family, The General, Farmers, and AIG, adding significant industry expertise to the board.
Kemper Corporation is an insurance company. It provides specialty auto, life, homeowners, and other personal insurance products across the United States.
6. Strive, Inc. (NASDAQ:ASST)
Stock Upside: 74.47%
Market Capitalization: $1.31 billion
Number of Hedge Fund Holders: 13
Strive, Inc. (NASDAQ:ASST) is one of the top small cap stocks with huge growth potential. On May 26, Strive, Inc. disclosed via an SEC Form 8-K that it had acquired 1,109 Bitcoin between May 19 and May 22 at an average price of $76,989 per coin, including fees. The new acquisition brings the company’s total Bitcoin treasury to 16,500 BTC and elevates it to seventh place among publicly listed corporate Bitcoin holders globally.
Strive said the May 19-22 purchase cost about $85.4 million and that the company funded the transaction using proceeds from its Variable Rate Series A Perpetual Preferred Stock. This is the company’s mechanism for raising capital to buy Bitcoin, and for that reason, Strive didn’t record any debt on its balance sheet.
As of the end of the transaction, May 22, Strive’s full treasury snapshot was $93.3 million in cash and cash equivalents, $50.1 million in Variable Rate Series A Perpetual Stretch Preferred Stock of Strategy Inc., and 16,500 BTC valued at approximately $1.27 billion, the filing shows.
Earlier in the month, on May 19, the company disclosed in another Form 8-K filing that it had bought nearly 382 BTC for $30.3 million between May 13 and May 18. Before that, and still in this May, the company had acquired 444 BTC for $33.9 million.
Strive, Inc. is a financial services and asset management company. It offers investment products focused on shareholder value maximization and corporate governance strategies.
5. National Vision Holdings, Inc. (NASDAQ:EYE)
Stock Upside: 74.52%
Market Capitalization: $1.37 billion
Number of Hedge Fund Holders: 28
National Vision Holdings, Inc. (NASDAQ:EYE) is one of the top small cap stocks with huge growth potential. On May 13, National Vision Holdings, Inc. reported its Q1 2026 financial results and stated that revenue came in at $543.9 million, up 6.6% year over year.
The CFO, Chris Laden, explained that the revenue growth came on the back of a 5.1% increase in average customer spend. However, per Laden, overall customer traffic declined 1.2%, as self-pay customers visited stores less frequently, a trend the CFO attributed to a volatile macro backdrop, including early-quarter winter storms and shifting consumer sentiment.
Adjusted EPS came in at $0.45, well ahead of the $0.43 that analysts expected. It was also higher than the $0.34 posted in Q1 2025. The CEO, Alex Wilkes, attributed the earnings beat to aggressive cost control measures the company undertook during the quarter. For example, lower payroll and advertising costs reduced selling, general and administrative expenses by 200 basis points as a percentage of revenue, Wilkes told investors on the earnings call.
The executives also highlighted the expansion of National Vision’s military partnership with the Army and Air Force Exchange Service (AAFES). Effective April 1, the company added 20 new optical locations on military bases, which made it the sole optical provider on all US Army and Air Force bases. This also brought its total AAFES footprint to 72 locations. Management noted this does not materially change 2026 financial projections.
National Vision Holdings, Inc. is an optical retail company. It provides eye exams, prescription eyewear, contact lenses, and vision care services through brands such as America’s Best Contacts & Eyeglasses and Eyeglass World.
4. Harrow, Inc. (NASDAQ:HROW)
Stock Upside: 74.67%
Market Capitalization: $1.31 billion
Number of Hedge Fund Holders: 22
Harrow, Inc. (NASDAQ:HROW) is one of the top small cap stocks with huge growth potential. On May 13, Cantor Fitzgerald analyst Steve Seedhouse lowered his price target on Harrow, Inc. from $91 to $88, while keeping his Overweight rating intact. The analyst made the move in response to Harrow’s downward revision to its near-term revenue expectations for VEVYE, the company’s flagship dry eye drug.
Harrow shared its Q1 2026 results on May 11. The company’s quarterly revenue came in at $44.2 million. Although the figure was lower than the $47.8 million in Q1 2025, management explained that the decline wasn’t too significant because it was largely due to a one-time $8 million gross-to-net revenue adjustment. This adjustment was linked to new VEVYE commercial coverage for high-deductible plan patients who surged beyond initial demand models.
The company detailed that VEVYE posted record new and total prescriptions despite an 18% decline in the overall branded dry eye market. Unit demand for IHEEZO, the company’s product for ocular anesthesia, rose 18% year over year, and 136% year over year for TRIESENCE.
Analyst Steve Seedhouse’s thesis dwelled more on VEVYE because this is Harrow’s flagship product. The analyst pointed to the one-time $8 million gross-to-net revenue adjustment and noted that it created a pricing pressure that hit Q1 revenue but is not expected to recur. For that reason, he cut revenue expectations for the product, and by extension, convinced him to adjust the price target.
Harrow, Inc. is an ophthalmic pharmaceutical company that develops and markets medicines for eye care treatments. Its portfolio includes products for glaucoma, dry eye disease, post-surgical care, and other ophthalmic conditions.
3. Intapp, Inc. (NASDAQ:INTA)
Stock Upside: 74.91%
Market Capitalization: $1.54 billion
Number of Hedge Fund Holders: 25
Intapp, Inc. (NASDAQ:INTA) is one of the top small cap stocks with huge growth potential. On May 5, Intapp, Inc. reported its Q3 FY2026 results where revenue reached $146.0 million, up 13% year over year and slightly ahead of the $143.9 million analyst consensus.
The report shows that the growth was primarily driven by the company’s cloud transition. That is, SaaS revenue surged 27% to $107.9 million, while legacy on-premise license revenue fell from $31.7 million to $24.8 million. The executives explained on the earnings call that this shift is evidence of the company growing its higher-quality recurring revenue while shedding lower-quality one-time license income.
Non-GAAP diluted EPS came in at $0.29, beating the forecasted $0.28. Management said the difference arose from revenue growth and improving operating leverage.
According to the report, the quarter’s biggest news was the formal launch of Celeste. This is Intapp’s agentic AI platform designed to handle multi-step, compliance-sensitive workflows across an entire professional firm. It targets what the company estimates is a $30+ billion addressable market across legal, accounting, consulting, and capital markets firms.
John Hall, Intapp’s Chairman and CEO, explained on the earnings call that Celeste “works as a standalone platform and as a context and compliance layer that makes other leading AI tools more effective inside a firm.” “We are re-architecting our core business applications to run as expert agents powered by Celeste,” he added.
Intapp, Inc. is a cloud software company. It provides AI-powered solutions for professional and financial services firms, including law firms, accounting companies, consulting firms, and investment banks.
2. Enovis Corporation (NYSE:ENOV)
Stock Upside: 82.98%
Market Capitalization: $1.33 billion
Number of Hedge Fund Holders: 34
Enovis Corporation (NYSE:ENOV) is one of the top small cap stocks with huge growth potential. On May 19, Enovis Corporation disclosed in an SEC filing that its shareholders approved five proposals, among them being an amendment to the company’s 2020 Omnibus Incentive Plan.
The amendment expands the pool of shares available for employee equity awards and significantly raises the compensation ceiling for independent board directors. It authorized an additional 3,650,000 shares of common stock for issuance under the 2020 plan. The amendment also raises the annual compensation cap for each independent director from $350,000 to $750,000. An exception allows the cap to reach up to 200% of the new $750,000 limit.
Separately, on May 7, Enovis reported its Q1 2026 financial results and said that it earned $589.2 million in revenue. The figure was 5.4% higher than in Q1 2025 and surpassed the $573 million analyst consensus. Non-GAAP adjusted EPS was $0.89 compared to $0.81 that Wall Street expected.
Ben Berry, Enovis CFO, told investors on the earnings call that the company revised its non-GAAP definitions following an SEC comment letter process. They removed the historical adjustment for inventory step-up charges related to the Lima acquisition.
Management maintained its outlook for revenue of $2.31-$2.37 billion, adjusted EBITDA of $425-$435 million, adjusted EPS of $3.52-$3.73, and free cash flow conversion above 25%.
Enovis Corporation is a medical technology company. It develops orthopedic and rehabilitation products, including surgical implants, braces, recovery systems, and digital healthcare solutions. The company serves healthcare providers and patients through its Reconstruction and Prevention & Recovery segments.
1. Huron Consulting Group Inc. (NASDAQ:HURN)
Stock Upside: 98.51%
Market Capitalization: $1.72 billion
Number of Hedge Fund Holders: 24
Huron Consulting Group Inc. (NASDAQ:HURN) is one of the top small cap stocks with huge growth potential. On May 5, Huron Consulting Group Inc. reported its Q1 2026 financial results in which it delivered record revenue before RBR of $443.7 million. The revenue was up 12.1% year over year and exceeded the analyst consensus of $438.2 million. Of that growth, $19.3 million came from acquisitions completed in late 2024.
According to the report, the Healthcare segment carried much of the weight with $225.2 million in income, which the company measures as revenues before reimbursable expenses, or RBR. The RBR growth was possible because of strong client demand for performance improvement, revenue cycle management, financial advisory, and strategy services.
Adjusted EPS reached $1.73, well ahead of the $1.61 analyst consensus and up 3% year over year. The report also noted that adjusted EBITDA rose 21.9% to $50.6 million, which lifted the adjusted EBITDA margin to 11.4% of RBR from 10.5% a year ago. John Kelly, the CFO, said on the earnings call that this improvement came despite a higher effective tax rate. To him, this is evidence that the underlying earnings quality was stronger than the headline growth implies.
Kelly concluded his session of the earnings call by telling investors that management fully reaffirmed the company’s outlook. That means the expected RBR remains in the $1.78-$1.86 billion range, 14.5%-15.0% of RBR for adjusted EBITDA margin, and $8.35-$9.15 for adjusted EPS.
Huron Consulting Group Inc. is a professional services firm. It provides management consulting, advisory, and digital transformation solutions primarily to healthcare organizations, higher education institutions, and commercial businesses.
READ NEXT: Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks and Top 10 Stocks to Buy for Long Term.
